PERTH, Australia – The pharma industry largely supports the Therapeutic Goods Administration's (TGA) update to its orphan drug regulations, expected to become effective July 1, though industry stakeholders offered some suggestions for modifications, mostly regarding eligibility criteria for orphan designation and the time lapse for the validity period.